DOI QR코드

DOI QR Code

The -765G>C Polymorphism in the Cyclooxygenase-2 Gene and Digestive System Cancer: a Meta-analysis

  • Zhao, Fen (Department of Pathophysiology, West China School of Preclinical and Forensic Medicine, Sichuan University) ;
  • Cao, Yue (Department of Physiology and Pathology, Basic Medicine College, Chengdu University of Traditional Chinese Medicine) ;
  • Zhu, Hong (Department of Abdominal Cancer, West China Hospital, Sichuan University) ;
  • Huang, Min (Department of Pathophysiology, West China School of Preclinical and Forensic Medicine, Sichuan University) ;
  • Yi, Cheng (Department of Abdominal Cancer, West China Hospital, Sichuan University) ;
  • Huang, Ying (Department of Pathophysiology, West China School of Preclinical and Forensic Medicine, Sichuan University)
  • Published : 2014.10.23

Abstract

Background: Published data regarding associations between the -765G>C polymorphism in cyclooxygenase-2 (COX-2) gene and digestive system cancer risk have been inconclusive. The aim of this study was to comprehensively evaluate the genetic risk of the -765G>C polymorphism in the COX-2 gene for digestive system cancer. Materials and Methods: A search was performed in Pubmed, Medline (Ovid), Embase, CNKI, Weipu, Wanfang and CBM databases, covering all studies until Feb 10, 2014. Statistical analysis was performed using Revman5.2. Results: A total of 10,814 cases and 16,174 controls in 38 case-control studies were included in this meta-analysis. The results indicated that C allele carriers (GC+CC) had a 20% increased risk of digestive system cancer when compared with the homozygote GG (odds ratio (OR)=1.20, 95% confidence interval (CI), 1.00-1.44 for GC+CC vs GG). In the subgroup analysis by ethnicity, significant elevated risks were associated with C allele carriers (GC+CC) in Asians (OR = 1.46, 95% CI=1.07-2.01, and p=0.02) and Africans (OR=2.12, 95% CI=1.57-2.87, and p< 0.00001), but not among Caucasians, Americans and mixed groups. For subgroup analysis by cancer type (GC+CC vs GG), significant associations were found between the -765G>C polymorphism and higher risk for gastric cancer (OR=1.64, 95% CI=1.03-2.61, and p=0.04), but not for colorectal cancer, oral cancer, esophageal cancer, and others. Regarding study design (GC+CC vs GG), no significant associations were found in then population-based case-control (PCC), hospital-based case-control (HCC) and family-based case-control (FCC) studies. Conclusions: This meta-analysis suggested that the -765G>C polymorphism of the COX-2 gene is a potential risk factor for digestive system cancer in Asians and Africans and gastric cancer overall.

Keywords

Cyclooxygenase-2;digestive system cancer;meta-analysis;polymorphism

Acknowledgement

Supported by : National Natural Science Foundation of China

References

  1. Bakhle YS (2001). COX-2 and cancer: a new approach to an old problem. Br J Pharmacol, 134, 1137-50. https://doi.org/10.1038/sj.bjp.0704365
  2. Akkiz H, Bayram S, Bekar A, et al (2011). Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma. Mol Cell Biochem, 347, 201-8. https://doi.org/10.1007/s11010-010-0629-9
  3. Andersen V, Ostergaard M, Christensen J, et al (2009). Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer, 9, 407. https://doi.org/10.1186/1471-2407-9-407
  4. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  5. Berlau J, Glei M, Pool-Zobel BL (2004). Colon cancer risk factors from nutrition. Anal Bioanal Chem, 378, 737-43. https://doi.org/10.1007/s00216-003-2284-4
  6. Bye H, Prescott NJ, Matejcic M, et al (2011). Populationspecific genetic associations with oesophageal squamous cell carcinoma in South Africa. Carcinogenesis, 32, 1855-61. https://doi.org/10.1093/carcin/bgr211
  7. Cao H, Xu Z, Long H, Li XQ (2010). The -765C allele of the cyclooxygenase-2 gene as a potential risk factor of colorectal cancer: a meta-analysis. Tohoku J Exp Med, 222, 15-21. https://doi.org/10.1620/tjem.222.15
  8. Cao Y, Prescott SM (2002). Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol, 190, 279-86. https://doi.org/10.1002/jcp.10068
  9. Cox DG, Pontes C, Guino E, et al (2004). Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer, 91, 339-43.
  10. Chang WS, Yang MD, Tsai CW, et al (2012). Association of cyclooxygenase 2 single-nucleotide polymorphisms and hepatocellular carcinoma in Taiwan. Chin J Physiol, 55, 1-7. https://doi.org/10.4077/CJP.2012.AMM056
  11. Chiang SL, Chen PH, Lee CH, et al (2008). Up-regulation of inflammatory signalings by areca nut extract and role of cyclooxygenase-2 -1195G>a polymorphism reveal risk of oral cancer. Cancer Res, 68, 8489-98. https://doi.org/10.1158/0008-5472.CAN-08-0823
  12. Cook MB, Kamangar F, Whiteman DC, et al (2010). Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst, 102, 1344-53. https://doi.org/10.1093/jnci/djq289
  13. Daraei A, Salehi R, Mohamadhashem F (2012). PTGS2 (COX2)-765G>C gene polymorphism and risk of sporadic colorectal cancer in Iranian population. Mol Biol Rep, 39, 5219-24. https://doi.org/10.1007/s11033-011-1319-8
  14. Dong J, Dai J, Zhang M, et al (2010). Potentially functional COX-2-1195G>A polymorphism increases the risk of digestive system cancers: a meta-analysis. J Gastroenterol Hepatol, 25, 1042-50. https://doi.org/10.1111/j.1440-1746.2010.06293.x
  15. Dubois RN, Abramson SB, Crofford L, et al (1998). Cyclooxygenase in biology and disease. FASEB J, 12, 1063-73.
  16. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  17. Gong Z, Bostick RM, Xie D, et al (2009). Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma. Int J Colorectal Dis, 24, 647-54. https://doi.org/10.1007/s00384-009-0656-8
  18. Gu KS, Chen Y (2012). Mechanism of P-glycoprotein expression in the SGC7901 human gastric adenocarcinoma cell line induced by cyclooxygenase-2. Asian Pac J Cancer Prev, 13, 2379-83. https://doi.org/10.7314/APJCP.2012.13.5.2379
  19. Harrison JR, Lorenzo JA, Kawaguchi H, et al (1994). Stimulation of prostaglandin E2 production by interleukin-1 alpha and transforming growth factor alpha in osteoblastic MC3T3-E1 cells. J Bone Miner Res, 9, 817-23.
  20. Gunter MJ, Canzian F, Landi S, et al (2006). Inflammationrelated gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev, 15, 1126-31. https://doi.org/10.1158/1055-9965.EPI-06-0042
  21. Guo Y, Zhang X, Tan W, et al (2007). Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms. Pharmacogenet Genomics, 17, 197-205. https://doi.org/10.1097/FPC.0b013e328010bda1
  22. Hamajima N, Takezaki T, Matsuo K, et al (2001). Genotype Frequencies of cyclooxygenease 2 (COX2) rare polymorphisms for Japanese with and without colorectal cancer. Asian Pac J Cancer Prev, 2, 57-62.
  23. He JH, Li YM, Zhang QB (2011). Cyclooxygenase-2 promoter polymorphism -899G/C is associated with hepatitis B-related liver cancer in a Chinese population of Gansu province. Chinese Med J, 124, 4193-7.
  24. Hoff JH, te Morsche RH, Roelofs HM, et al (2009). COX-2 polymorphisms -765G-->C and -1195A-->G and colorectal cancer risk. World J Gastroenterol, 15, 4561-5. https://doi.org/10.3748/wjg.15.4561
  25. Hou L, Grillo P, Zhu ZZ, et al (2007). COX1 and COX2 polymorphisms and gastric cancer risk in a Polish population. Anticancer Res, 27, 4243-7.
  26. Huang F, Lin C, Shi YH, et al (2013). MicroRNA-101 inhibits cell proliferation, invasion, and promotes apoptosis by regulating cyclooxygenase-2 in Hela cervical carcinoma cells. Asian Pac J Cancer Prev, 14, 5915-20. https://doi.org/10.7314/APJCP.2013.14.10.5915
  27. Iglesias D, Nejda N, Azcoita MM, et al (2009). Effect of COX2-765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control, 20, 1421-9. https://doi.org/10.1007/s10552-009-9368-1
  28. Kristinsson JO, van Westerveld P, te Morsche RH, et al (2009). Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma. World J Gastroenterol, 15, 3493-7. https://doi.org/10.3748/wjg.15.3493
  29. Jongthawin J, Techasen A, Loilome W, et al (2012). Antiinflammatory agents suppress the prostaglandin E2 production and migration ability of cholangiocarcinoma cell lines. Asian Pac J Cancer Prev, 13, 47-51.
  30. Kamal MM, Youssef OZ, Lotfy AN, et al (2012). Association of folate intake, dietary habits, smoking and COX-2 promotor-765G>C polymorphism with K-ras mutation in patients with colorectal cancer. J Egypt Natl Canc Inst, 24, 115-22. https://doi.org/10.1016/j.jnci.2012.05.002
  31. Koh WP, Yuan JM, van den Berg D, et al (2004). Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese health study. Br J Cancer, 90, 1760-4.
  32. KX Z, YM L, X L (2008). Association of COX-2 genetic polymorphisms and Hpylori infection with gastric cancer in high-incidence Hexi area of Gansu Province in China. Shijie Huaren Xiaohua Zazhi, 16, 2364-70.
  33. Leahy KM, Koki AT, Masferrer JL (2000). Role of cyclooxygenases in angiogenesis. Curr Med Chem, 7, 1163-70. https://doi.org/10.2174/0929867003374336
  34. Li Y, Dai L, Zhang J, et al (2012). Cyclooxygenase-2 polymorphisms and the risk of gastric cancer in various degrees of relationship in the Chinese Han population. Oncol Lett, 3, 107-12.
  35. Liang Y, Liu JL, Wu Y, et al (2011). Cyclooxygenase-2 polymorphisms and susceptibility to esophageal cancer: a meta-analysis. Tohoku J Exp Med, 223, 137-44. https://doi.org/10.1620/tjem.223.137
  36. Lin YC, Huang HI, Wang LH, et al (2008). Polymorphisms of COX-2 -765G>C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol, 44, 798-804. https://doi.org/10.1016/j.oraloncology.2007.10.006
  37. Moons LM, Kuipers EJ, Rygiel AM, Groothuismink AZ (2007). COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. Am J Gastroenterol, 102, 2373-9. https://doi.org/10.1111/j.1572-0241.2007.01373.x
  38. Liu F, Pan K, Zhang X, et al (2006). Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology, 130, 1975-84. https://doi.org/10.1053/j.gastro.2006.03.021
  39. Liu JL, Liang Y, Wang ZN (2010). Cyclooxygenase-2 polymorphisms and susceptibility to gastric carcinoma: a meta-analysis. World J Gastroenterol, 16, 5510-7. https://doi.org/10.3748/wjg.v16.i43.5510
  40. Mittal M, Kapoor V, Mohanti BK, Das SN (2010). Functional variants of COX-2 and risk of tobacco-related oral squamous cell carcinoma in high-risk Asian Indians. Oral Oncol, 46, 622-6. https://doi.org/10.1016/j.oraloncology.2010.06.002
  41. Papafili A, Hill MR, Brull DJ, et al (2002). Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol, 22, 1631-6. https://doi.org/10.1161/01.ATV.0000030340.80207.C5
  42. Pereira C, Pimentel-Nunes P, Brandao C, et al (2010). COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur J Gastroenterol Hepatol, 22, 607-13. https://doi.org/10.1097/MEG.0b013e3283352cbb
  43. Pereira C, Sousa H, Ferreira P (2006). -765G>C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol, 12, 5473-8.
  44. Pharoah PD, Dunning AM, Ponder BA, Easton DF (2004). Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer, 4, 850-60. https://doi.org/10.1038/nrc1476
  45. Saad N, Esa NM, Ithnin H (2013). Suppression of beta-catenin and cyclooxygenase-2 expression and cell proliferation in azoxymethane-induced colonic cancer in rats by rice bran phytic acid (PA). Asian Pac J Cancer Prev, 14, 3093-9. https://doi.org/10.7314/APJCP.2013.14.5.3093
  46. Sitarz R, Leguit RJ, de Leng WW, et al (2008). The COX-2 promoter polymorphism -765 G>C is associated with earlyonset, conventional and stump gastric cancers. Modern Pathology, 21, 685-90. https://doi.org/10.1038/modpathol.2008.36
  47. Saxena A, Prasad KN, Ghoshal UC (2008). Polymorphism of 765G C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection A study from northern India. World J Gastroenterol, 14, 1498-503. https://doi.org/10.3748/wjg.14.1498
  48. Seibert K, Zhang Y, Leahy K, et al (1994). Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA, 91, 12013-7. https://doi.org/10.1073/pnas.91.25.12013
  49. Shin WG, Kim HJ, Cho SJ (2012). The COX-2-1195AA genotype is associated with diffuse-type gastric cancer in Korea. Gut Liver, 6, 321-7. https://doi.org/10.5009/gnl.2012.6.3.321
  50. Szczeklik W, Sanak M, Szczeklik A (2004). Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol, 114, 248-53. https://doi.org/10.1016/j.jaci.2004.05.030
  51. Talar-Wojnarowska R, Gasiorowska A, Olakowski M, et al (2011). Role of cyclooxygenase-2 gene polymorphisms in pancreatic carcinogenesis. World J Gastroenterol, 17, 4113-7. https://doi.org/10.3748/wjg.v17.i36.4113
  52. Tan W, Wu J, Zhang X, et al (2007). Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis, 28, 1197-201. https://doi.org/10.1093/carcin/bgl242
  53. Tang XF, Li YM, Li SX ( 2009). Correlation between the nucleotide polymorphisms of COX-2 and the susceptibility to gastric cancer in Hui ethnic group. Shijie Huaren Xiaohua Zazhi, 17, 1772-6.
  54. Tatsuguchi A, Matsui K, Shinji Y, et al (2004). Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol, 35, 488-95. https://doi.org/10.1016/j.humpath.2003.10.025
  55. Ulrich CM, Whitton J, Yu JH, et al (2005). PTGS2 (COX-2) -765G>C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev, 14, 616-9. https://doi.org/10.1158/1055-9965.EPI-04-0510
  56. Tazawa R, Xu XM, Wu KK, Wang LH (1994). Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun, 203, 190-9. https://doi.org/10.1006/bbrc.1994.2167
  57. Thompson CL, PLummer SJ, Merkulova A (2009). No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterology, 15, 2240. https://doi.org/10.3748/wjg.15.2240
  58. Ueda N, Maehara Y, Tajima O, et al (2008). Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: the Self Defense Forces Health Study. Cancer Sci, 99, 576-81. https://doi.org/10.1111/j.1349-7006.2007.00711.x
  59. Upadhyay R, Jain M, Kumar S, et al (2009). Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squmaous cell carcinoma. Mutat Res, 663, 52-9. https://doi.org/10.1016/j.mrfmmm.2009.01.007
  60. Wang J, Joshi AD, Corral R, et al (2012). Carcinogen metabolism genes, red meat and poultry intake, and colorectal cancer risk. Int J Cancer, 130, 1898-907. https://doi.org/10.1002/ijc.26199
  61. Wang MT, Honn KV, Nie D (2007). Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev, 26, 525-34. https://doi.org/10.1007/s10555-007-9096-5
  62. Wang XF, Huang MZ, Zhang XW, et al (2013). COX-2-765G>C polymorphism increases the risk of cancer: a meta-analysis. PLoS One, 8, 73213. https://doi.org/10.1371/journal.pone.0073213
  63. Wu KK (1996). Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic roles. J Lab Clin Med, 128, 242-5. https://doi.org/10.1016/S0022-2143(96)90023-2
  64. Xing LL, Wang ZN, Jiang L, et al (2008). Cyclooxygenase 2 polymorphism and colorectal cancer: -765G>C variant modifies risk associated with smoking and body mass index. World J Gastroenterol, 14, 1785-9. https://doi.org/10.3748/wjg.14.1785
  65. Zhang X, Miao X, Tan W, et al (2005). Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology, 129, 565-76.
  66. Xu D, ZHANG XM, Zhao P (2008). Association between single nucleotide polymorphisms in the promoter of cyclooxygenase COX-2 gene and hereditary susceptibility to pancreatic cancer. National Medical J China, 88, 1961-5.
  67. Yaghoobi M, Rakhshani N, Sadr F, et al (2004). Hereditary risk factors for the development of gastric cancer in younger patients. BMC Gastroenterol, 4, 28. https://doi.org/10.1186/1471-230X-4-28
  68. Yan WF, Sun PC, Nie CF (2013). Cyclooxygenase-2 polymorphisms were associated with the risk of gastric cancer: evidence from a meta-analysis based on case-control studies. Tumour Biol, 34, 3323-30. https://doi.org/10.1007/s13277-013-0901-1
  69. Zhang X, Zhong R, Zhang Z, et al (2011). Interaction of cyclooxygenase-2 promoter polymorphisms with Helicobacter pylori infection and risk of gastric cancer. Molecular Carcinogenesis, 50, 876-83. https://doi.org/10.1002/mc.20784
  70. Zhang XM, Miao XP, Tan W (2006). Genetic polymorphisms in the promoter region of cyclooxygenase-2 and their association with risk of gastric cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 28, 119-23.
  71. Zhang XM, Zhong R, Liu L (2011). Smoking and COX-2 functional polymorphisms interact to increase the risk of gastric cardia adenocarcinoma in Chinese population. PLoS One, 6, 21894. https://doi.org/10.1371/journal.pone.0021894
  72. Zhang YG, Huang J, Zhang J, et al (2010). RANTES gene polymorphisms and asthma risk: A meta-analysis. Arch Med Res, 41, 50-8. https://doi.org/10.1016/j.arcmed.2010.01.002
  73. Zhao D, Xu D, Zhang X, et al (2009). Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology, 136, 1659-68. https://doi.org/10.1053/j.gastro.2009.01.071

Cited by

  1. The P275A Polymorphism in the Macrophage Scavenger Receptor 1 Gene and Prostate Cancer Risk: a Meta-Analysis vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5407
  2. COX-2 rs689466, rs5275, and rs20417 polymorphisms and risk of head and neck squamous cell carcinoma: a meta-analysis of adjusted and unadjusted data vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2535-3
  3. POLYMORPHISM OF THE COX-2 GENE AND SUSCEPTIBILITY TO COLON AND RECTAL CANCER vol.30, pp.2, 2017, https://doi.org/10.1590/0102-6720201700020008